

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-96)

TALDITERCEPT ALFA

PRONUNCIATION

tal dit' er sept al' fa

THERAPEUTIC CLAIM

Treatment of ALS, Duchenne muscular dystrophy and spinal muscular atrophy

CHEMICAL NAMES

1. Adnectin, anti-(human growth differentiation factor 8) (synthetic clone PRD-1474 fibronectin type III tenth domain (10Fn3)-based isoform
2. Human Ig gamma-1 chain C region (IGHG1*01 Fc fragment)-(6-230)-peptidyl-L-Glu-L-Leu-L-Gln-L-Leu-L-Glu-L-Glu-L-Glu-L-Ser-L-Ala-L-Ala-L-Glu-L-Ala-L-Gln-L-GluGly-L-Glu-L-Leu-L-GluGly-human fibronectin-(1447-1468)-peptidyl-L-Ser-L-Leu-L-Pro-L-His-L-GlnGly-L-Lys-L-Ala-L-Asn-human fibronectin-(1477-1498)-peptidyl-L-Ser-L-Lys-L-Ser-human fibronectin-(1502-1522)-peptidyl-Gly-L-ArgGly-L-Asp-L-Ser-L-Pro-L-Ala-L-Ser-L-Ser-human fibronectin-(1532-1542)-peptide, dimer (6-6':9-9')-bisdisulfide

STRUCTURAL FORMULA

Monomer sequence

DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	50
PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	100
CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	LPPSRDELTK	NQVSLTCLVK	150
GFYPSDIAVE	WESNGQPENN	YKTTTPVLDS	DGSFFLYSKL	TVDKSRWQQG	200
NVFSCSVMHE	ALHNNHTQKS	LSLSPQLQLE	ESAAEAQEGE	LEGVSDVPRD	250
LEVVAATPTS	LLISWLSLPHQ	GKANYRITY	GETGGNSPVQ	EFTVPGRGVT	300
ATISGLKPGV	DYTIIVYAVT	VTDITGYLKIK	PISINRYTEI		340

Disulfide bridges

6-6' 9-9' 41-101 41'-101' 147-205 147'-205'

Glycosylation sites (N)

Asn-77 Asn-77''

MOLECULAR FORMULA

$C_{3386}H_{5242}N_{882}O_{1048}S_{16}$ (dimer)

MOLECULAR WEIGHT

75.6 kDa (nonglycosylated)

TRADEMARK

None as yet

SPONSOR

Roche/Bristol-Myers Squibb

CODE DESIGNATIONS

RO7239361

CAS REGISTRY NUMBER

1580555-26-5

UNII

766C38JSAR

WHO NUMBER

10661

gbk